TABLE OF CONTENTS
INVESTIGATORâ€™S AGREEMENT.............................................................................................................................2 PROTOCOL SYNOPSIS ..............................................................................................................................................3 STUDY GLOSSARY..................................................................................................................................................12 TABLE OF CONTENTS ............................................................................................................................................16 LIST OF IN-TEXT TABLES......................................................................................................................................18 LIST OF IN-TEXT FIGURES ....................................................................................................................................19 1. OBJECTIVES .....................................................................................................................................................20 2. DISEASE BACKGROUND AND RATIONALE..............................................................................................21 2.1. Diffuse Large B-cell Lymphoma ...........................................................................................................21 2.2. Primary Mediastinal B-cell Lymphoma and Transformed Follicular Lymphoma .................................22 2.3. High Grade B-cell Lymphoma ...............................................................................................................23 2.4. Study Rationale ......................................................................................................................................23 2.4.1. CD19 and Expression...........................................................................................................24 2.4.2. Anti-CD19 CAR T-cell Product...........................................................................................24 2.4.3. Prior Experience with Axicabtagene Ciloleucel and other Anti-CD19 CAR T Cells.........................................................................................................................25 2.4.4. Axicabtagene Ciloleucel.......................................................................................................25 3. STUDY DESIGN................................................................................................................................................26 3.1. General Study Design ............................................................................................................................26 3.2. Participating Sites...................................................................................................................................29 3.3. Number of Subjects................................................................................................................................29 3.4. Replacement of Subjects ........................................................................................................................30 3.5. Study Duration .......................................................................................................................................30 3.5.1. Study Duration for Individual Subjects ................................................................................30 3.5.2. Completion of the Phase 2 Pivotal Study .............................................................................30 4. SUBJECT SCREENING AND ENROLLMENT...............................................................................................31 5. SUBJECT ELIGIBILITY ...................................................................................................................................32 5.1. Inclusion Criteria....................................................................................................................................32 5.2. Exclusion Criteria...................................................................................................................................34 6. PROTOCOL TREATMENT ..............................................................................................................................37 6.1. Treatment Terminology..........................................................................................................................37 6.2. Study Treatment .....................................................................................................................................37 6.2.1. Bridging Therapy for Phase 2 Safety Management Study, Cohort 3 (retreatment), Cohort 4, and Cohort 6 ..................................................................................37 6.2.2. Debulking Therapy for Phase 2 Safety Management Study, Cohort 5 .................................38 6.2.3. Conditioning Chemotherapy ................................................................................................39 6.2.4. Axicabtagene Ciloleucel.......................................................................................................40 6.2.5. Concomitant Therapy ...........................................................................................................41 6.2.6. Excluded Medications ..........................................................................................................41 6.2.7. Subsequent Therapy .............................................................................................................42 6.3. Study Treatment Schedule .....................................................................................................................42 6.3.1. Leukapheresis (Within Approximately 5 Days of Eligibility Confirmation).......................................................................................................................42 6.3.2. Study Treatment ...................................................................................................................43 6.3.3. Rationale for Study Treatment Dosing.................................................................................44 6.3.4. Study Treatment by Phase ....................................................................................................50 6.4. Toxicity Management ............................................................................................................................53 6.4.1. Phase 2 Safety Management Study (Cohort 4 and Cohort 6 only) .......................................53 6.4.2. Phase 2 Safety Management Study (Cohort 5).....................................................................57 7. STUDY PROCEDURES ....................................................................................................................................58 7.1. Informed Consent...................................................................................................................................58 7.2. Demographic Data .................................................................................................................................58 7.3. Medical and Treatment History..............................................................................................................58 7.4. Physical Exam, Vital Signs, Performance Status, and EQ-5D ...............................................................58 7.5. Neurological Assessment .......................................................................................................................59 7.6. Cardiac Function ....................................................................................................................................60 7.7. Magnetic Resonance Imaging ................................................................................................................60 7.8. Bone Marrow Biopsy .............................................................................................................................60 7.9. Lumbar Puncture ....................................................................................................................................60 7.10. Disease Response Assessment ...............................................................................................................61 7.11. Laboratory ..............................................................................................................................................62 7.12. Biomarkers .............................................................................................................................................63 7.13. Description of Study Periods..................................................................................................................65 7.13.1. Screening..............................................................................................................................65 7.13.2. Rescreening ..........................................................................................................................67 7.13.3. Enrollment/Leukapheresis....................................................................................................67 7.13.4. Bridging Therapy Phase 2 Safety Management Study .........................................................68 7.13.5. Debulking Therapy Phase 2 Safety Management Study, Cohort 5 ......................................68 7.13.6. Conditioning Chemotherapy Period .....................................................................................69 7.13.7. Investigational Product Treatment Period ............................................................................71 7.13.8. Post-treatment Assessment Period .......................................................................................74 7.13.9. Long-term Follow-up Period ................................................................................................76 7.13.10. Retreatment ..........................................................................................................................78 8. SUBJECT WITHDRAWAL ...............................................................................................................................84 8.1. Reasons for Removal from Treatment ...................................................................................................84 8.2. Reasons for Removal from Study ..........................................................................................................85 9. SAFETY REPORTING ......................................................................................................................................86 9.1. Adverse Events.......................................................................................................................................86 9.2. Reporting of Adverse Events .................................................................................................................86 9.2.1. Reporting Abnormal Laboratory Findings ...........................................................................87 9.3. Definition of Serious Adverse Events ....................................................................................................88 9.4. Reporting of Serious Adverse Events ....................................................................................................89 9.5. Reporting Deaths....................................................................................................................................89 9.6. Diagnosis versus Signs and Symptoms ..................................................................................................90 9.7. Pregnancy and Lactation ........................................................................................................................90 9.8. Hospitalization and Prolonged Hospitalization ......................................................................................90 9.9. Abnormal Vital Sign Values ..................................................................................................................91 9.10. Safety Review Team and Dose-limiting Toxicity ..................................................................................91 9.11. Data Safety Monitoring Board ...............................................................................................................93 9.12. Criteria to Pause Enrollment ..................................................................................................................93 10. STATISTICAL CONSIDERATIONS ................................................................................................................94 10.1. Hypothesis..............................................................................................................................................94 10.2. Study Endpoints .....................................................................................................................................94 10.2.1. Primary .................................................................................................................................94 10.2.2. Secondary .............................................................................................................................94 CCI 10.3. Sample Size Considerations ...................................................................................................................95 10.3.1. Phase 2 Pivotal Study, Cohort 1, and Cohort 2 ....................................................................96 10.3.2. Phase 2 Safety Management Study ......................................................................................97 10.4. Statistical Assumptions ..........................................................................................................................98 10.5. Analysis Subsets.....................................................................................................................................98 10.5.1. Phase 1 Study .......................................................................................................................98 10.5.2. Phase 2 Study .......................................................................................................................99 10.6. Access to Individual Subject Treatment Assignments ...........................................................................99 10.7. Interim Analysis ...................................................................................................................................100 10.7.1. Interim Analysis and Early Stopping Rules .......................................................................100 10.7.2. Safety Interim Analysis ......................................................................................................100 10.7.3. Efficacy Interim Analysis...................................................................................................100 10.8. Planned Method of Analysis ................................................................................................................101 10.8.1. Objective Response Rate....................................................................................................102 10.8.2. Duration of Response .........................................................................................................102 10.8.3. Progression-free Survival ...................................................................................................102 10.8.4. Overall Survival .................................................................................................................102 10.8.5. Safety..................................................................................................................................102 10.8.6. Long-term Data Analysis ...................................................................................................102 11. REGULATORY OBLIGATIONS....................................................................................................................103 11.1. Independent Review Board/Independent Ethics Committee ................................................................103 11.2. Subject Confidentiality.........................................................................................................................103 11.3. Investigator Signatory Obligations.......................................................................................................103 12. PROTOCOL AMENDMENTS AND TERMINATION ..................................................................................104 13. STUDY DOCUMENTATION AND ARCHIVE .............................................................................................105 14. STUDY MONITORING AND DATA COLLECTION ...................................................................................106 15. PUBLICATION ................................................................................................................................................107 16. COMPENSATION ...........................................................................................................................................108 17. REFERENCES .................................................................................................................................................109 18. APPENDICES ..................................................................................................................................................115 Appendix A Revised IWG Response Criteria for Malignant Lymphoma (Cheson et al, 2007) ..............116 Appendix B Monitoring of subjects after IP administration per country regulatory agencies: .................118